Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China

Wei, Hongtao; Cui, Can; Cui, Xiangli; Liu, Yi; Li, Dandan

doi:10.1186/s12913-021-06084-1

Table 1 Base-case model variables and ranges used in a sensitivity analysis

From: Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China

Variable	Value	Range	Reference
Probabilities
Probability of ischemic stroke caused by different drugs
Warfarin	0.04	0.023–0.0453	[18,19,20]
Rivaroxaban	0.0193	NA	[19]
Dabigatran110mg	0.0183	0.0167–0.0189	[18, 19]
Dabigatran150mg	0.0137	NA	[20]
Probability of ischemic stroke outcome by severity
Light	0.091	0.091–0.133	[21]
Moderate	0.425	0.348–0.425	[21]
Severe	0.402	0.402–0.417	[21]
Die(in 30day)	0.082	0.082–0.101	[21]
Probability of ICH caused by different drugs
Warfarin	0.0121	0.0057–0.0294	[18, 19, 22]
Rivaroxaban	0.00257	0.0021–0.0033	[19, 22]
Dabigatran110mg	0.00359	0.0028–0.0039	[18, 19]
Dabigatran150mg	0.0027	NA	[18]
Probability of ICH outcome by severity
Light	0.12	NA	[21, 23]
Moderate	0.27	NA	[21, 23]
Severe	0.43	NA	[21, 23]
Die	0.18	NA	[21, 23]
Probability of ECH caused by different drugs
Warfarin	0.027	NA	[24]
Rivaroxaban	0.03	NA	[23]
Dabigatran110mg	0.007	NA	[24]
Dabigatran150mg	0.0217	NA	[23]
Probability of ECH outcome by severity
Die	0.0147	0.01–0.04	[21]
Probability of MI caused by different drugs
Warfarin	0.0098	NA	[21]
Rivaroxaban	0.0098	NA	[21]
Dabigatran110mg	0.0072	NA	[18]
Dabigatran150mg	0.0074	NA	[18]
Probability of MI outcome by severity
Death	0.166	0.158–0.174	[21, 25]
All-cause mortality by different drugs
Warfarin	0.026	0.0258–0.0261	[18, 22]
Rivaroxaban	0.0164	NA	[22]
Dabigatran110mg	0.0333	NA	[18]
Dabigatran150mg	0.0219	NA	[18]
Cost
Price (specification/$)		Range of daily dose
warfarin	3 mg/0.07	1.5 mg-6 mg/d
Rivaroxaban	20 mg/4.87	15–20 mg qd
Dabigatran110mg	110 mg/2.34	110–150 mg bid
Dabigatran150mg	150 mg/3.01	110–150 mg bid
Cost of examination and service	10.77	NA
Frequency about examination/Annual
warfarin	21	NA	[26]
Rivaroxaban and Dabigatran	1	NA
Total cost $(drug and examination)
Warfarin	253.30	239.70-280.51
Rivaroxaban	1787.00	1435.86-2844.52
Dabigatran110mg	1718.21	1711.17-2206.93
Dabigatran150mg	2206.93	1711.17-2206.93
Event
Stroke	1351.20	851.36-2681.69
ICH	2605.43	1935.86-3862.05
ECH	1216.72	867.23-2516.68
MI	3875.18	1805.02-5529.89
Health utility values in each state
Light	0.76	0.7–0.9	[27]
Moderate	0.39	0.1–0.5	[27]
Severe	0.16	0.0-0.32	[27]
ICH	0.8	0.79–0.84	[28]
ECH	0.8	0.79–0.84	[28]
MI	0.84	0.67–0.96	[29]

ICH Intracranial hemorrhage; ECH Extracranial hemorrhage; MI Myocardial infarction

Back to article page

ISSN: 1472-6963

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Health Services Research

Contact us